Rigel Pharmaceuticals | RIGL - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
Agenus USD 39.21M 49.82M 2026-03
Amgen USD 2.08B 570M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
AstraZeneca USD 4.81B 894M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Celldex Therapeutics USD -78.68M 2.63M 2026-03
Daiichi Sankyo JPY -6.52B 113.25B 2026-03
Eli Lilly USD 8.85B 583.8M 2026-03
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Pfizer USD -653M 5.84B 2026-06
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Veracyte USD 26.52M 3.45M 2026-06